SI-BONE 2025 Q1 Earnings Strong Performance as Net Loss Improves 40%

SI-BONE(SIBN) reported its fiscal 2025 Q1 earnings on May 06th, 2025. SI-BONE Inc exceeded revenue expectations, reporting $47.3 million compared to the analyst estimate of $45.17 million. The company raised its full-year guidance, now expecting worldwide revenue between $193.5 million and $197.5 million, reflecting growth of approximately 16% to 18%, and positive adjusted EBITDA for the full year 2025. This marks an improvement from previous guidance which projected a slightly lower upper range for revenue growth.

Revenue
The total revenue of SI-BONE increased by 24.9% to $47.29 million in 2025 Q1, up from $37.87 million in 2024 Q1.

Earnings/Net Income
SI-BONE narrowed losses to $0.15 per share in 2025 Q1 from a loss of $0.27 per share in 2024 Q1 (44.4% improvement). Meanwhile, the company successfully narrowed its net loss to $-6.54 million in 2025 Q1, reducing losses by 40.0% compared to the $-10.90 million net loss reported in 2024 Q1. Despite improved metrics, profitability challenges remain.

Price Action
The stock price of SI-BONE has climbed 3.85% during the latest trading day, has surged 15.20% during the most recent full trading week, and has surged 20.96% month-to-date.

Post-Earnings Price Action Review
Investing in SI-BONE shares following a quarter with decreased revenue and holding for 30 days has historically yielded a 9.16% annual return over the past five years, with 66.88% of months in the portfolio showing positive returns. The strategy experienced a maximum drawdown of 23.55% between January 1, 2022, and September 30, 2022, with a recovery period of 18 months. The portfolio's best year was 2019, achieving a 24.02% return, while 2022 marked the worst year with a -17.95% return. This approach reflects the market's response to SI-BONE's financial performance and investor sentiment during fluctuating periods.

CEO Commentary
“Our momentum continues unabated with a strong start to 2025, as we outperformed across all our key value creation metrics,” said Laura Francis, Chief Executive Officer. She highlighted the company’s stellar revenue growth, improved gross margins, and the achievement of profitability targets. The record addition of over 300 active physicians reflects the rapid adoption of new products launched in the past year. Francis emphasized that SI-BONE's focus on innovation, strong commercial execution, and operational rigor has built a resilient platform poised for continued outsized revenue growth.

Guidance
SI-BONE expects 2025 worldwide revenue to be in the range of $193.5 million to $197.5 million, indicating year-over-year growth of approximately 16% to 18%. The company estimates a full-year gross margin of 78% and anticipates operating expenses to grow at around 10% at the revenue midpoint. SI-BONE also expects to deliver positive adjusted EBITDA for the full year 2025, with no material impact from recently announced tariffs.

Additional News
SI-BONE Inc announced its participation in the 2025 BofA Securities Healthcare Conference in Las Vegas, scheduled for May 13, 2025, where management will conduct a fireside chat. The company has also reported record financial results for the fourth quarter of 2024 and issued guidance for 2025. Additionally, SI-BONE is preparing for favorable changes due to the CMS FY 2026 proposed hospital inpatient rule, set to affect its New Technology Add-On Payment starting October 1, 2025, potentially increasing financial viability for procedures using its products.